All News

Top news of the day from across the health care landscape.

In recent months, legislation to increase access to pre- and post-exposure prophylaxis (PrEP and PEP) passed in California with a vote of 34-1 in the Senate and a unanimous vote in the Assembly.

A phase 3 study evaluated the safety and efficacy of oral paclitaxel versus intravenous paclitaxel monotherapy in patients with metastatic breast cancer.

What is causing this person to cough up blood after he quit smoking cigarettes and a tobacco pipe?

Aspirin therapy found to improve liver function test results and survival after transarterial embolization for hepatocellular carcinoma.

Top news of the day from across the health care landscape.

Officials with the FDA have approved AbbVie’s upadacitinib (Rinvoq) 15 mg, once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).

Study recommends similar clinical thresholds for diagnosing and managing giant cell arteritis for patients of different ethnicities.

Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

A phase 4 head-to-head trial compared ixekizumab (Taltz) with guselkumab (Tremfya) in patients with moderate-to-severe plaque psoriasis.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The approval of fedratinib (Inrebic, Celgene) provides another treatment option for patients with myelofibrosis, a rare bone marrow disorder.

Officials with the FDA have granted approval to entrectinib (Rozlytrek, Genentech) for 2 different cancer indications.

The dug will be commercially available to healthcare professionals and appropriate patients in the U.S. in the fourth quarter of 2019.

Top news of the day from across the health care landscape.

HIV-related immunosuppression may contribute to an elevated risk of cancer-related morbidity in elderly patients with the disease.

If approved, acalabrutinib (Calquence, AstraZeneca) will offer a chemotherapy-free treatment option for adults with chronic lymphocytic leukemia.

An analysis of a quality improvement project at an oncology specialty pharmacy showed that pharmacist interventions can reduce financial toxicity for patients.

Top news of the day from across the health care landscape.

High body mass index is associated with an increased risk of chronic diseases such as type 2 diabetes, cancer, musculoskeletal, and respiratory conditions.

Officials with the FDA have approved Alembic Pharmaceuticals’ Fenofibrate Tablets USP, 48 mg and 145 mg as an adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), Triglycerides and apolipoprotein B (Apo B).

Artificial intelligence able to recognize patterns in gene sequences and molecular data from breast cancer, which oncologists are now evaluating in clinical trials.

A phase 3 trial evaluated dupilumab (Dupixent, Regeneron and Sanofi) in children from 6 to 11 years of age with severe atopic dermatitis.

Alembic Pharmaceuticals has received FDA approval for Dorzolamide Hydrochloride Ophthalmic Solution USP, 2%, therapeutically equivalent to Trusopt Ophthalmic Solution, 2% (Merck Sharp & Dohme Corp.).

Top news of the day from across the health care landscape.

Genomind is expanding its mental health genetic testing services with the addition of Genomind Professional PGx Express, which provides a more focused report and set of services to enhance the preexisting mental health genetic test.

The number of first-degree relatives affected by blood cancer and age of diagnosis may contribute to the likelihood of a family member’s risk of being diagnosed with the same disease.

Investigators believe that urine sampling can be used to diagnose and treat bladder cancer.

Top news of the day from across the health care landscape.